Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6782,965-   
Low Rs4842,576-   
Sales per share (Unadj.) Rs198.21,701.8-  
Earnings per share (Unadj.) Rs18.5106.3-  
Cash flow per share (Unadj.) Rs35.0243.9-  
Dividends per share (Unadj.) Rs3.0093.06-  
Dividend yield (eoy) %0.53.4 15.4%  
Book value per share (Unadj.) Rs186.31,890.4-  
Shares outstanding (eoy) m805.70848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.91.6 180.0%   
Avg P/E ratio x31.426.1 120.3%  
P/CF ratio (eoy) x16.611.4 146.2%  
Price / Book Value ratio x3.11.5 212.7%  
Dividend payout %16.287.5 18.5%   
Avg Mkt Cap Rs m468,0312,349,435 19.9%   
No. of employees `00022.644.9 50.4%   
Total wages/salary Rs m28,5650-   
Avg. sales/employee Rs Th7,053.132,108.3 22.0%   
Avg. wages/employee Rs Th1,261.50-   
Avg. net profit/employee Rs Th659.12,005.8 32.9%   
INCOME DATA
Net Sales Rs m159,7101,443,107 11.1%  
Other income Rs m4,7660-   
Total revenues Rs m164,4751,443,107 11.4%   
Gross profit Rs m30,973395,196 7.8%  
Depreciation Rs m13,263116,648 11.4%   
Interest Rs m1,68428,345 5.9%   
Profit before tax Rs m20,791250,203 8.3%   
Minority Interest Rs m-1721,137 -15.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-164,244 0.0%   
Tax Rs m5,695-3,055 -186.4%   
Profit after tax Rs m14,92490,150 16.6%  
Gross profit margin %19.427.4 70.8%  
Effective tax rate %27.4-1.2 -2,243.6%   
Net profit margin %9.36.2 149.6%  
BALANCE SHEET DATA
Current assets Rs m124,266974,669 12.7%   
Current liabilities Rs m37,715849,994 4.4%   
Net working cap to sales %54.28.6 627.3%  
Current ratio x3.31.1 287.3%  
Inventory Days Days9191 99.8%  
Debtors Days Days9596 98.9%  
Net fixed assets Rs m105,190471,350 22.3%   
Share capital Rs m1,6113,552 45.4%   
"Free" reserves Rs m148,5110-   
Net worth Rs m150,1231,603,018 9.4%   
Long term debt Rs m38,301737,892 5.2%   
Total assets Rs m239,6333,297,961 7.3%  
Interest coverage x13.39.8 135.8%   
Debt to equity ratio x0.30.5 55.4%  
Sales to assets ratio x0.70.4 152.3%   
Return on assets %6.93.6 192.9%  
Return on equity %9.95.6 176.8%  
Return on capital %11.84.9 240.0%  
Exports to sales %34.70-   
Imports to sales %00-   
Net fx Rs m38,3680-   
CASH FLOW
From Operations Rs m16,911229,956 7.4%  
From Investments Rs m-16,687-81,483 20.5%  
From Financial Activity Rs m-3,487-275,848 1.3%  
Net Cashflow Rs m-3,451-127,375 2.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.04 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare CIPLA With: PLETHICO PHARMA  LUPIN  FULFORD INDIA  ORCHID PHARMA LTD  SUVEN LIFESCIENCES  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views On News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound? (Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 14, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS